Delaware Ankylosing Spondylitis Infusion Center of DE

No. Some biologic medications are administered through an intravenous infusion, while others are injected under the skin. The prescribing rheumatologist selects the medication and method of administration based on disease activity, previous treatment response, other health conditions, safety considerations, insurance coverage, and the patient’s individual needs.

A rheumatologist or another qualified prescribing specialist determines whether an intravenous biologic medication is appropriate. The decision is based on symptoms, disease activity, previous medication response, imaging or laboratory findings, medical history, and possible treatment risks. Infusion Center of DE administers the prescribed therapy and coordinates care with the referring provider.

Before certain biologic medications are started, the prescribing provider may request tuberculosis screening, hepatitis testing, blood counts, liver or kidney tests, and a review of vaccination history. The required screening depends on the medication and the patient’s health history. Testing helps identify infections or other concerns that could affect treatment safety.

Patients should contact the infusion team before their appointment if they have a fever, active infection, worsening cough, open wound, or have recently started antibiotics. The healthcare team may consult the prescribing provider to determine whether treatment should proceed or be delayed. Patients should not make that decision without speaking with their medical team.

Infusion time varies according to the medication, prescribed dose, treatment protocol, and whether an observation period is required. Some appointments may take about an hour, while others can take several hours. The infusion team can provide a more accurate time estimate after receiving the medication order from the prescribing specialist.

The dosing schedule depends on the specific medication. Some treatments begin with several starter doses given closer together, followed by maintenance infusions at longer intervals. Patients should follow the schedule ordered by their prescribing provider because receiving doses too early, too late, or inconsistently may affect treatment response and safety monitoring.

Bring a current medication list, insurance information, photo identification, and any documents requested by the clinic. Patients may also bring a book, headphones, tablet, or another quiet activity. Wearing comfortable clothing with sleeves that allow access to the arm can make IV placement and monitoring easier.

Many patients can drive themselves after treatment, but this depends on the medication, premedications, individual response, and the prescribing provider’s instructions. Some premedications may cause drowsiness. Patients receiving a new medication or a treatment that has previously caused symptoms may be advised to arrange transportation.

Contact the infusion center and prescribing provider as soon as possible. The dose should not automatically be given late or rescheduled without reviewing the medication’s dosing requirements. The healthcare team will determine the appropriate new appointment date and whether any additional evaluation or authorization is needed before treatment resumes.

Patients should report fever, signs of infection, severe rash, difficulty breathing, chest tightness, facial swelling, persistent dizziness, or other unusual symptoms. Emergency symptoms require immediate medical attention. Less urgent effects, such as headache, fatigue, or mild nausea, should still be discussed with the infusion team or prescribing provider if they persist or worsen.

Infusion Center of DE primarily administers infusion therapy according to an order from a qualified prescribing provider. The referring rheumatologist or specialist generally selects the medication, dose, and treatment schedule. The infusion team reviews the order, coordinates necessary documentation, administers treatment, monitors the patient, and communicates relevant concerns to the prescriber.